Status:

ACTIVE_NOT_RECRUITING

Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Conditions:

Cervical Cancer

Endometrial Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to see if a radioactive substance called 18F-Fluorodeoxyglucose (18F- FDG), injected into the cervix during a PET/CT scan done before surgery can show us more clearly whic...

Eligibility Criteria

Inclusion

  • The study population will include women with stage IB1 cervical cancer (any histologic subtype) deemed eligible for surgery, and women with a clinical stage I high-grade endometrial cancer planning to undergo surgical staging. High grade is defined by the following:
  • Uterine serous carcinoma
  • Clear cell endometrial carcinoma
  • Grade 3 endometrioid carcinoma
  • Endometrial carcinosarcoma
  • Clinical stage I grade 1-2 endometrial cancer also eligible with deep myoinvasion ≥ 50% shown on preop MRI and/or elevated preop CA-125 \> 35 U/ml.
  • Age ≥18 years
  • Hemoglobin ≥10 g/dL
  • Plasma albumin ≥3 g/dL
  • GOG performance status ≤2
  • Plasma glucose ≤200 mg/dL
  • Plasma creatinine ≤1.6
  • Well-controlled hypertension
  • Medical clearance for surgery and considered an appropriate surgical candidate
  • Negative serum pregnancy test, if of child-bearing potential
  • If, based on surgeon's assessment, the patient is recommended to undergo surgical staging for histologically confirmed endometrial cancer or if IB1 cervical cancer is deemed eligible for surgical treatment of disease
  • Participation in other research protocols does not exclude a patient from participation in this study

Exclusion

  • Hemoglobin \<10 g/dL
  • Plasma albumin \<3 g/dL
  • GOG performance status \>2
  • Plasma glucose \>200 mg/dL
  • Renal insufficiency with plasma creatinine \>1.6
  • Uncontrolled hypertension
  • Patient does not meet medical clearance for surgery and is not considered an appropriate surgical candidate
  • Pregnancy
  • For Stage 2:
  • Patient who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers of non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc.
  • Patients with a metallic hip implant or any other metallic implant or device in the pelvis that might distort local magnetic field and compromise quality of MRI

Key Trial Info

Start Date :

November 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2026

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT02285192

Start Date

November 1 2014

End Date

November 1 2026

Last Update

December 30 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Memorial Sloan Kettering Basking Ridge (Consent only)

Basking Ridge, New Jersey, United States, 07920

2

Memorial Sloan Kettering Monmouth (Consent only)

Middletown, New Jersey, United States, 07748

3

Memorial Sloan Kettering Bergen (Consent only)

Montvale, New Jersey, United States, 07645

4

Memorial Sloan Kettering Commack (Consent only)

Commack, New York, United States